Enbrel - Worldwide - Overview

Enbrel

All Financial Data in US $ (mln)

Worldwide

Overview

Word Search (Top 10 - by date)

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Coherus BioSciences (July 16, 2014)

Global Biological Drugs Market is Expected to Reach USD 287,139.7 Million in 2020: Transparency Market Research (July 16, 2014)

CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
CEL-SCI (July 15, 2014)

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Protalix BioTherapeutics (June 18, 2014)

AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
Bristol-Myers Squibb (June 10, 2014)

Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors
Ironwood Pharmaceuticals (June 04, 2014)

Oncos Therapeutics Recruits Dr Magnus Jaderberg as CMO to Strengthen its Focus on Cancer Immunotherapy
Oncos Therapeutics (June 04, 2014)

Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
Pfizer (May 23, 2014)

Bristol-Myers Squibb to Present New Remission Data on ORENCIA® (abatacept) and Clazakizumab at The European League Against Rheumatism (EULAR) 2014 Annual Meeting
Bristol-Myers Squibb (May 21, 2014)

PFIZER REPORTS FIRST-QUARTER 2014 RESULTS
Pfizer (May 05, 2014)

Displaying 10 out of a possible 609 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product:	Enbrel
Generic Name:	etanercept
Therapeutic Subcategory:	Other anti-rheumatics
Therapeutic Subcategory:	Anti-virals

Product Sales Summary 2010/11

				Annual Sales WW - Sales		Growth per Year (%)
	Rank¹	Generic Name	Therapeutic Subcategory	2010	2011	2011
Enbrel²				7,257	7,892	+9%
	Note: Shaded Cells³

Clinical Trial Coverage: No. of Trials involving Product

	Trial Count
Enbrel⁴	391

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

2011 Product Sales analysis
Download analysis into Excel
Search 2 yrs of company press releases

Research Codes Synonyms

Product:

Enbrel

Ranked on:
Annual Sales WW
2011

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.